Phase I
It was a relatively quiet week for clinical trial news. Here’s a look.
The trial remains on clinical hold and continues to indefinitely delay the company’s plans to seek regulatory approval for the treatment.
Following approval of its coronavirus vaccine, the first in the world, Russia plans to initiate a new study involving 40,000 people as the country looks to boost production and distribute the drug to patients in that country, as well as to patients in countries it has struck deals with.
Today’s data describes key safety and immunogenicity data from the U.S. Phase I study for BNT162b.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 21, 2020.
Despite the urgent need for more research into the coronavirus, the New York Times reported on August 14 that there have been numerous testing delays, staffing shortages and space constraints tying up the process.
Shares of Poseida Therapeutics plunged more than 20% in premarket trading this morning after the company announced the U.S. Food and Drug Administration halted a cancer drug trial due to safety concerns.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 19, 2020.
The 11-person team at Codagenix may be tiny, but it has big plans for the company’s new COVID-19 vaccine.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
PRESS RELEASES